SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Body mass index and cancer survival: a meta-analysis of cohort studies.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Letter to the editor regarding: 'The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer'.Annals of medicine · 2026Article
- Prognostic value of the HALP score in patients with testicular cancer: a retrospective study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to evaluate the association between BMI and OS in patients with cancer by a combination of available evidence.
methodsArticles published from January 1st 2019 to June 1st 2024 were identified from PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and Wan Fang Library. Cohort studies including adult patients (≥ 18 years), who were confirmed with cancer and followed for 12 months or more, and whose BMI measurements and OS were available, were included. We used both fixed and random-effects models to estimate overall hazard ratios (HRs) for OS. The primary outcome was OS. The exposure was BMI, which was further classified into four groups based on both WHO and Chinese criteria.
resultsThe current meta-analysis included 36 studies, involving 123,913 cancer patients (56,951 men and 66,962 women, medium follow-up 41.3 months). Compared with cancer patients with normal weight, the estimated HRs of OS for underweight was 1.43 (95% CI: 1.30, 1.56; I
conclusionUnderweight was significantly associated with worse OS in cancer patients. If analyzed separately, only overweight but not obesity had a moderately favorable effect on cancer survival.
Indexed as
Identifiers
40347406What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.